URGN
$18.59
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Intraday
Recent News
UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push
UroGen Pharma (NasdaqGM:URGN) reported new Phase 3 ENVISION trial analyses for ZUSDURI in recurrent low grade intermediate risk non muscle invasive bladder cancer, showing strong efficacy across risk groups. The company highlighted high complete response rates and durable benefit in a patient population with limited treatment options. UroGen also secured an expanded US$250 million non dilutive term loan with a fixed interest rate and no financial covenants to support clinical and commercial...
UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...
UroGen Pharma Ltd (URGN) reports a 21% revenue increase, driven by successful product launches, despite a widening net loss and increased operational costs.
Urogen Pharma Q4 Earnings Call Highlights
Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product Jelmyto, and a strengthened balance sheet following a refinancing with Pharmakon Advisors. Management a
UroGen (URGN) Q4 2025 Earnings Call Transcript
Joining me today are Elizabeth A. Barrett, President and Chief Executive Officer; Mark P. Schoenberg, Chief Medical Officer; David Lin, Chief Commercial Officer; and Christopher Degnan, Chief Financial Officer. On today's call, we will be making certain forward-looking statements.
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?